Tri Locum Partners LP Regeneron Pharmaceuticals, Inc. Transaction History

Tri Locum Partners LP

$374 Million
Q3 2024

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$883.2 - $1071.19 $7.9 Million - $9.59 Million	8,949 Added 104.46%	17,516 $18.4 Million
Q1 2024 May 15, 2024	SELL	$902.69 - $993.35 $6.72 Million - $7.4 Million	-7,445 Reduced 46.5%	8,567 $8.25 Million
Q4 2023 Feb 14, 2024	SELL	$775.18 - $881.7 $3.1 Million - $3.52 Million	-3,997 Reduced 19.98%	16,012 $14.1 Million
Q3 2023 Nov 14, 2023	SELL	$692.45 - $844.37 $439,705 - $536,174	-635 Reduced 3.08%	20,009 $16.5 Million
Q2 2023 Aug 14, 2023	SELL	$700.03 - $830.35 $15.9 Million - $18.9 Million	-22,745 Reduced 52.42%	20,644 $14.8 Million
Q1 2023 May 15, 2023	BUY	$680.49 - $826.97 $29.5 Million - $35.9 Million	43,389 New	43,389 $35.7 Million
Q3 2022 Nov 14, 2022	BUY	$573.97 - $724.32 $17.3 Million - $21.8 Million	30,115 New	30,115 $20.7 Million
Q2 2022 Aug 15, 2022	SELL	$548.35 - $738.84 $11.8 Million - $15.9 Million	-21,477 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$595.12 - $698.43 $12.8 Million - $15 Million	21,477 New	21,477 $15 Million
Q4 2021 Feb 14, 2022	SELL	$543.48 - $670.97 $7.58 Million - $9.36 Million	-13,950 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$574.03 - $680.96 $35.4 Million - $42 Million	-61,677 Reduced 81.55%	13,950 $8.44 Million
Q2 2021 Aug 16, 2021	BUY	$472.8 - $558.54 $5.16 Million - $6.1 Million	10,922 Added 16.88%	75,627 $42.2 Million
Q1 2021 May 17, 2021	BUY	$446.73 - $548.2 $24.2 Million - $29.8 Million	54,282 Added 520.79%	64,705 $30.6 Million
Q4 2020 Feb 16, 2021	BUY	$478.3 - $607.98 $4.99 Million - $6.34 Million	10,423 New	10,423 $5.04 Million

Others Institutions Holding REGN

# of Institutions

1,529

Shares Held

82.7M

Call Options Held

1.22M

Put Options Held

1.51M

View Full List

About REGENERON PHARMACEUTICALS, INC.

Ticker REGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,190,000
Market Cap $74.7B
Description
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...

More about REGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Tri Locum Partners LP, based on Form 13F filings with the SEC.

News

Stay updated on Tri Locum Partners LP with notifications on news.

Account